Table 1 Patient characteristics
Characteristics | Description | N | % |
|---|---|---|---|
Number of patients | 88 | ||
Number of CAR treatments | 93 | ||
Number of leukaphereses | 88 | ||
Age at start of bridging therapy | Median (min—max) in years | 10.45 (0.95—31.1) | |
< 10 years | 44 (93) | 47.3 | |
10—20 years | 42 (93) | 45.2 | |
20—30 years | 5 (93) | 5.4 | |
> 30 years | 2 (93) | 2.2 | |
Gender | Male | 61 (88) | 69.3 |
Female | 27 (88) | 30.7 | |
Diagnosis | B-lineage ALL | 88 (88) | 100 |
BCR-ABL status | BCR-ABL positive | 7 (88) | 8.0 |
Ph-like translocation | 1 (88) | 1.1 | |
CAR product | Tisagenlecleucel | 81 (93) | 87.1 |
Experimental CAR T cell product | 8 (93) | 8.6 | |
N/A | 4 (93) | 4.3 | |
r/r disease status | 1st relapse | 26 (93) | 28.0 |
2nd relapse | 44 (93) | 47.3 | |
Subsequent relapses | 16 (93) | 17.2 | |
Primary refractory | 4 (93) | 4.3 | |
N/A | 3 (93) | 3.2 | |
Prior transplantation | no prior SCT | 23 (93) | 24.7 |
1 SCT | 61 (93) | 65.6 | |
> 1 SCT | 9 (93) | 9.7 | |
Autologous SCT | 1 (93) | 1.1 | |
Prior immunotherapy | No prior immunotherapy | 47 (93) | 50.5 |
Prior blinatumomab | 38 (93) | 40.9 | |
Prior inotuzumab | 19 (93) | 20.4 | |
Prior CAR T cells | 7 (93) (1/93 N/A) | 7.5 | |
Lymphodepletion regimen | Fludarabine/CP | 84 (93) | 90.3 |
CP/daunorubicine/VCR | 1 (93) | 1.1 | |
no lymphodepletion | 6 (93) | 6.5 | |
N/A | 2 (93) | 2.2 |